$STLN insider trading
Over the last 12 months, Starling Oncology insiders reported 11 buys totaling $2.4M and 8 sales totaling $21.6M across SEC Form 4 filings. 16% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- $2.4M 11 events
- Sold · 12m
- $21.6M 8 events
- Events · 12m
- 19 Form 4 filings, grouped
- Insiders · 12m
- 7 distinct reporters
- 10b5-1 share
- 16% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | Chernett Jorey10% | ▲ Buy | 12,000 | $6.54 | $78K | +0.1% | — |
| Jul 21, 2026 | Chernett Jorey10% | ▲ Buy | 18,000 | $5.27 | $95K | +0.2% | — |
| Jul 14, 2026 | Podnos YaleChief Medical Officer · O | ▼ Sale | 23,452 | $6.41 | $150K | -8.3% | plan · 2 tranches |
| Jul 10, 2026 | Chernett Jorey10% | ▲ Buy | 15,000 | $5.85 | $88K | +0.1% | — |
| Jun 23, 2026 | Chernett Jorey10% | ▲ Buy | 18,000 | $5.02 | $90K | +0.2% | — |
| Jun 8, 2026 | Podnos YaleChief Medical Officer · O | ▼ Sale | 23,451 | $5.38 | $126K | -8.3% | plan |
| Jun 4, 2026 | Chernett Jorey10% | ▲ Buy | 12,000 | $4.75 | $57K | +0.1% | — |
| Apr 16, 2026 | Kaushal MohitD | ▼ Sale | 95,719 | $3.5 | $335K | -35.7% | plan · 2 tranches |
| Apr 9, 2026 | Chernett Jorey10% | ▲ Buy | 20,000 | $3.1 | $62K | +0.2% | — |
| Mar 27, 2026 | Chernett Jorey10% | ▲ Buy | 27,429 | $2.96 | $81K | +0.3% | — |
| Mar 26, 2026 | Chernett Jorey10% | ▲ Buy | 50,000 | $3.15 | $158K | +0.5% | — |
| Mar 24, 2026 | Chernett Jorey10% | ▲ Buy | 125,000 | $3.11 | $389K | +1.2% | — |
| Mar 20, 2026 | Chernett Jorey10% | ▲ Buy | 25,000 | $3.35 | $84K | +0.2% | — |
| Mar 17, 2026 | Chernett Jorey10% | ▲ Buy | 398,985 | $3.07 | $1.2M | +4% | 3 tranches |
| Jan 2, 2026 | Carter Robert RossChief Financial Officer · O | ▼ Sale | 247 | $3.56 | $879 | -0.1% | — |
| Dec 15, 2025 | Hively BradD | ▼ Sale | 13,333 | $3.77 | $50K | -1.9% | — |
| Nov 18, 2025 | Pacala Mark LD | ▼ Sale | 50,000 | $4 | $200K | -22.2% | 3 tranches |
| Sep 4, 2025 | M33 Growth I L.P.D·10% | ▼ Sale | 681,832 | $3.09 | $2.1M | -53.6% | indirect |
| Sep 4, 2025 | M33 Growth I L.P.D·10% | ▼ Sale | 6,018,168 | $3.09 | $18.6M | -43.1% | — |
| Aug 19, 2025 | Hively BradD | ▼ Sale | 20,221 | $4.06 | $82K | -3.1% | — |
Every $STLN filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Starling Oncology filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $STLN feed.